Dr. Martin's research is focused on rapid generation of new knowledge through clinical studies that can be brought back to the bedside to directly inform the care of patients with advanced lipid disorders and those in need of state-of-the-art comprehensive CV prevention. Members of his lab commit to complete ownership of their project, unwavering pursuit of excellence, and thrive on multidisciplinary teamwork. Active projects include the Very Large Database of Lipids, CASCADE FH Registry, MiCORE (Myocardial infarction, COmbined device, Recovery Enhancement), Google Health Search Trial, and mActive-Smoke. For more information, please visit the Ciccarone Center.

The key research interests in the Robert Bollinger Lab include identifying biological and behavioral risk factors for HIV transmission as well as characterizing the clinical progression and treatment of HIV and related infectious diseases. We also have a long-standing interest in optimizing health care capacity and delivery in settings with limited resources. Our work includes implementing science research projects to explore the effectiveness of initiatives such as task-shifting, clinical education, distance learning and mobile health programs as a way to improve health care in these locations.

Research in the Rahul Koka Lab focuses on pediatric airways, patient safety and health disparities. Recent studies have focused on the relationship between socioeconomic status and perioperative outcomes and patient safety factors related to interoperative cardiac arrests. We also performed effects analyses of the maintenance and repair of anesthetic equipment in various medical environments.

Research in the Rasika Mathias Lab focuses on the genetics of asthma in people of African ancestry. Our work led to the first genomewide association study of its kind in 2009. Currently, we are analyzing the whole-genome sequence of more than 1,000 people of African ancestry from the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA). CAAPA’s goal is to use whole-genome sequencing to expand our understanding of how genetic variants affect asthma risk in populations of African ancestry and to provide a public catalog of genetic variation for the scientific community. We’re also involved in the study of coronary artery disease though the GeneSTAR Program, which aims to identify mechanisms of atherogenic vascular diseases and attendant comorbidities.

Research in the Robert Gilman Lab focuses on disease control. Our work led to the development of microscopic-observation drug-susceptibility (MODS), a rapid tuberculosis diagnostic technique. We continue to conduct infectious disease research based at Peru’s Universidad Peruana Cayetano Heredia.

The Advocacy and Research on Reproductive Wellness of Incarcerated People (ARRWIP) group was founded in 2017 by Dr. Carolyn Sufrin of Johns Hopkins Complex Family Planning Serivces. The goal of our research is to create opportunities to improve reproductive wellbeing for people affected by the criminal legal system – including making full-scope, compassionate reproductive health care accessible for people experiencing incarceration and advocating for alternatives to incarceration.

Research in the Romsai Boonyasai Lab focuses on systems-based approaches for improving health care quality, including reducing harm during care transitions after hospital discharge and improving outcomes related to hypertension and other chronic diseases. We recently have focused on developing and evaluating practice-based tools for improving the accuracy of blood pressure measurement, overcoming clinical inertia to treatment, and engaging patients in self-management of their health.

Research in the Gregory Kirk Lab examines the natural history of viral infections — particularly HIV and hepatitis viruses — in the U.S. and globally. As part of the ALIVE (AIDS Linked to the Intravenous Experience) study, our research looks at a range of pathogenetic, clinical behavioral issues, with a special focus on non-AIDS-related outcomes of HIV, including cancer and liver and lung diseases. We use imaging and clinical, genetic, epigenetic and proteomic methods to identify and learn more about people at greatest risk for clinically relevant outcomes from HIV, hepatitis B and hepatitis C infections. Our long-term goal is to translate our findings into targeted interventions that help reduce the disease burden of these infections.

The Jonathan Weiner Lab researches the impact of electronic health records (EHRs), e-health and other health information technology (HIT) on populations, integrated delivery systems and public health agencies.

Research in the John Matthew Austin Lab explores health care performance measures, with a goal of improving patient care by enabling healthcare providers to view data about their performance, track patient outcomes and comply with best care practices. Our lab is currently working to develop performance measures for the ICU part, and we are part of The Leapfrog Group, an annual survey of U.S. hospitals that compares hospital performance on national measures of safety, quality and efficiency. Our research also explores the use of scientifically sound decision-support tools for guiding improvements in healthcare delivery systems.